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OBJECTIVE—Increased plasma concentrations of apolipopro-
tein B100 often present in patients with insulin resistance and
confer increased risk for the development of atherosclerosis.
Naturally occurring polyphenolic compounds including ﬂavonoids
have antiatherogenic properties. The aim of the current study was
to evaluate the effect of the polymethoxylated ﬂavonoid nobiletin
on lipoprotein secretion in cultured human hepatoma cells (HepG2)
and in a mouse model of insulin resistance and atherosclerosis.
RESEARCH DESIGN AND METHODS—Lipoprotein secretion
was determined in HepG2 cells incubated with nobiletin or in-
sulin. mRNA abundance was evaluated by quantitative real-time
PCR, and Western blotting was used to demonstrate activation of
cell signaling pathways. In LDL receptor–deﬁcient mice (Ldlr
2/2)
fed a Western diet supplemented with nobiletin, metabolic param-
eters, gene expression, fatty acid oxidation, glucose homeostasis,
and energy expenditure were documented. Atherosclerosis was
quantitated by histological analysis.
RESULTS—In HepG2 cells, activation of mitogen-activated pro-
tein kinase-extracellular signal–related kinase signaling by nobile-
tin or insulin increased LDLR and decreased MTP and DGAT1/2
mRNA, resulting in marked inhibition of apoB100 secretion.
Nobiletin, unlike insulin, did not induce phosphorylation of the
insulin receptor or insulin receptor substrate-1 and did not stimu-
late lipogenesis. In fat-fed Ldlr
2/2 mice, nobiletin attenuated dysli-
pidemia through a reduction in VLDL-triglyceride (TG) secretion.
Nobiletin prevented hepatic TG accumulation, increased expres-
sion of Pgc1a and Cpt1a, and enhanced fatty acid b-oxidation.
Nobiletin did not activate any peroxisome proliferator–activated
receptor (PPAR), indicating that the metabolic effects were
PPAR independent. Nobiletin increased hepatic and peripheral
insulin sensitivity and glucose tolerance and dramatically atten-
uated atherosclerosis in the aortic sinus.
CONCLUSIONS—Nobiletin provides insight into treatments for
dyslipidemia and atherosclerosis associated with insulin-resistant
states. Diabetes 60:1446–1457, 2011
I
nsulin resistance and type 2 diabetes are conditions
classically deﬁned by glucose intolerance but are
also characterized by lipid abnormalities including
an overproduction of hepatic VLDL (1). Increased
VLDL secretion contributes to increased plasma concen-
trations of apolipoprotein B100 (apoB100)-containing lip-
oproteins, which represents an important risk factor for
cardiovascular disease, especially because current phar-
macological interventions provide limited beneﬁt for cor-
recting VLDL overproduction (2). Insulin resistance reduces
the ability of the hepatic LDL receptor (LDLR) to mediate
lipoprotein reuptake and degradation (3,4), increases mi-
crosomal triglyceride transfer protein (MTP) expression
(5), and increases the hepatic synthesis of cholesterol and
triglyceride (TG) (6). Hepatic accumulation of lipids and
enhanced MTP-mediated transfer of these lipids onto the
apoB100 backbone are key determinants of VLDL secretion
(7,8). Concurrent with impaired lipid homeostasis, abnor-
mal glucose metabolism is observed in insulin-resistant
states as a result of impaired glucose uptake by peripheral
tissues and enhanced hepatic gluconeogenesis (9).
Hyperinsulinemia can initiate the transcription of sterol
regulatory element–binding protein 1c (SREBP1c), result-
ing in upregulation of genes involved in fatty acid (FA)
synthesis (10), contributing to both hepatic steatosis and
dyslipidemia (11). This is clearly observed in mice de-
ﬁcient in the hepatic insulin receptor (IR), where despite
hyperinsulinemia, hepatic SREBP1c-mediated lipogenesis,
hepatic TG, and VLDL-TG secretion are signiﬁcantly
reduced (12,13). Although not a target of SREBP1c, inhibi-
tion of insulin-induced mitogen-activated protein kinase-
extracellular signal–related kinase (MAPK)
erk signaling
increases DGAT1/2 expression leading to microsomal TG
accumulation and VLDL secretion (14). In concert with in-
creased lipogenesis, the reduced FA oxidation observed in
insulin resistance states further contributes to increased
hepatic lipid availability (15). Pgc1a and Ppara are key
regulators of hepatic FA oxidation, since in both Pgc1a
2/2
and Ppara
2/2 mice b-oxidation is impaired, leading to in-
creased hepatic lipid accumulation (16,17).
The hypocholesterolemic and metabolically beneﬁcial
properties of citrus-derived ﬂavonoids have been demon-
strated (18–22). Tangeretin, a polymethoxylated ﬂavonoid,
reduced apoB100 secretion from human hepatoma (HepG2)
cells through inhibition of both DGAT activity and mi-
crosomal TG accumulation (23). In a mouse model of
dyslipidemia and hyperinsulinemia, naringenin prevented
hyperinsulinemia-stimulated de novo lipogenesis, inhibited
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ORIGINAL ARTICLEVLDL-apoB secretion, and improved plasma lipids (24). In
insulin-resistant hamsters, a combination of tangeretin and
another polymethoxylated ﬂavonoid nobiletin ameliorated
dyslipidemia and improved glucose tolerance (18). Nobi-
letin increased Glut4 expression in muscle and attenuated
the hyperglycemia normally observed in ob/ob mice (25).
In Ldlr
2/2 or apoE
2/2 mice, naringenin, resveratrol, and
other polyphenolic compounds reduce atherosclerosis
through a variety of mechanisms, suggesting they have
powerful antiatherogenic properties (26–28).
The objective of the current study was to determine the
effectiveness of the citrus-derived ﬂavonoid nobiletin, to
inhibit apoB100 secretion from HepG2 cells, and to at-
tenuate dyslipidemia, insulin resistance, and atheroscle-
rosis. We demonstrate that nobiletin, like insulin, inhibits
apoB100 secretion from HepG2 cells through activation of
MAPK
erk signaling. In contrast with insulin, the effect of
nobiletin was independent of either IR or IR substrate-1
(IRS-1) tyrosine phosphorylation. Activation of MAPK
erk
by both nobiletin and insulin decreased the expression of
MTP and DGAT1/2 and increased LDLR expression. In
Ldlr
2/2 mice fed a Western diet, nobiletin prevented dys-
lipidemia and hepatic lipid accumulation, without any
change in caloric intake, intestinal TG absorption, or lean
body mass. Hepatic TG accumulation was prevented
by nobiletin through an increase in Pgc1a and Cpt1a ex-
pression leading to activation of hepatic FA oxidation.
VLDL-TG secretion was signiﬁcantly decreased by nobile-
tin. Nobiletin reduced peripheral lipid accumulation, im-
proved glucose tolerance, and restored insulin sensitivity
in liver and peripheral tissues, compared with Western-fed
mice. Nobiletin prevented atherosclerotic lesion develop-
ment, suggesting that amelioration of the dyslipidemia,
hepatic steatosis, and insulin resistance in Western-fed
Ldlr
2/2 mice attenuates plaque formation.
RESEARCH DESIGN AND METHODS
Cell culture and chemicals. Nobiletin (R&S PharmChem, Hangzhou City,
China) was solubilized in DMSO. HepG2 cells from the American Type Culture
Collection (Rockville, MD) were grown as described previously (29). All
inhibitors and inactive isoforms (MEK1/2: U0126 and U0124; p38MAPK:
SB203580 and SB248080 [Calbiochem, San Diego, CA]; MTP: BMS197636
[Bristol-Myers Squibb, Princeton, NJ]) were solubilized in DMSO. AICAR
(Sigma, St. Louis, MO) was solubilized in H2O.
Cellular and tissue assays. For gene expression, total RNA was isolated from
HepG2 cells or mouse liver (TRIzol; Invitrogen, Mississauga, Ontario, Canada),
and quantitative real-time PCR (qRT-PCR) was performed as previously de-
scribed (24). Immunoprecipitation and immunoblotting of IR and IRS-1, apoB100
secretion into media, and pERK-to-ERK ratios in cell lysates was performed as
described previously (20,21). A peroxisome proliferator–activated receptor
(PPAR)-responsive element luciferase assay was carried out in HepG2 cells
transfected with 0.01 mg/mL PPAR-a,- g,o r- d.SG5 expression vectors; 0.5
mg/mL PPRE.tk.Luc; and 0.05 mg/mL tk.pRL vectors (provided by Dr. John
Capone, McMaster University, Hamilton, Ontario, Canada) (30). FA oxidation
assays were performed as previously described (31). DiI-LDL,1’-dioctadecyl-
3,3,39,39-tetramethyl-indocarbocyanine perchlorate (Biomedical Technologies,
Stoughton, MA) was added at 10 ng/mL media for 5 h. Cells were trypsinized,
suspended in PBS, and ﬁltered. Mean ﬂuorescent signals were determined
by ﬂow cytometry (10
4 cells/sample) using FACS Calibur (BD Biosciences).
TG mass was measured as described previously (32). Synthesis of FA or TG
was measured following incubation of cells in 5% human lipoprotein-
deﬁcient serum (LPDS) with insulin or nobiletin by incorporation of [1-
14C]
acetic acid (Amersham Biosciences, Piscataway, NJ) into FA or incorporation of
[1-
14C] oleic acid (Amersham Biosciences) into TG (33). MTP activity was de-
termined using a modiﬁed isotopic transfer assay (32). See Supplementary Data
for details.
Animals. Male Ldlr
2/2 mice on the C57BL/6 background were obtained from
Jackson Laboratory (Bar Harbor, ME). Studies were performed in accordance
with the Canadian Guide for the Care and Use of Laboratory Animals and were
approved by the University of Western Ontario Animal Care Committee.
Twelve-week-old mice were fed ad libitum a chow diet (14% of calories from
fat; Harlan Teklad T8604, Madison, WI), a high-fat Western diet (TD96125, 42%
of calories from fat, no added cholesterol [0.05%] or cholate), or the Western
diet supplemented with 0.1 or 0.3% (weight/weight) nobiletin for 8 or 26
weeks. Food intake was measured daily, and body weight was measured bi-
weekly. Animals were fasted for 6 h before intervention. Intestinal fat ab-
sorption was determined using a modiﬁed fecal isotope ratio method (29).
Blood samples, tissue collection, and VLDL-TG secretion. Blood and
tissue collection from mice was as described previously (24). In vivo secretion
rates of VLDL-TG into plasma were determined in conscious, unrestrained
mice (18/group), following intraperitoneal injection of 1 g/kg tyloxapol (Ruger
Chemical Company, Irvington, NJ) (34). See Supplementary Data for details.
Energy expenditure, adiposity index, and FA oxidation. Energy expen-
diture was determined by an indirect open-circuit calorimeter (Oxylet; Panlab,
Cornella, Spain), and adiposity index was determined as the wet weight of the
epididymal fat pads/total body weight (24). Hepatic FA oxidation was de-
termined as the conversion of [
3H]palmitate to
3H20 (24). See Supplementary
Data for details.
Hyperinsulinemic-euglycemic clamp and pyruvate tolerance test. Clamps
were performed as previously described (35,36). See Supplementary Methods for
details. Pyruvate tolerance tests were performed in fasted mice (16 h) injected
(intraperitoneally) with 2 g/kg sodium pyruvate (Sigma). Insulin and glucose
tolerance tests were as described previously (24). Blood glucose was monitored
by a glucometer (Ascensia Elite; Bayer Healthcare, Toronto, Canada).
Statistical analysis. All data are presented as the mean 6 SEM. Analysis was
performed using Sigmaplot Version 14.0. Signiﬁcant differences (P , 0.05)
between groups were determined by a one-way ANOVA and post hoc Tukey
test to determine statistical signiﬁcance.
RESULTS
Nobiletin decreases apoB100 secretion through acti-
vation of MAPK
erk
. In HepG2 cells, nobiletin dose-
dependently reduced the secretion of apoB100-containing
lipoproteins into the media (Fig. 1A). Secretion of apoE
was unaffected (data not shown). The concentration of
nobiletin that inhibited apoB100 secretion by 50% (10 mM)
was used for further experiments. Insulin has been shown
to decrease apoB100 secretion through activation of
MAPK
erk signaling (20). Incubation of cells with a speciﬁc
inhibitor of MEK1/2, U0126, demonstrated that nobiletin,
like insulin, reduces apoB100 accumulation through acti-
vation of MAPK
erk (Fig. 1B). The activity of MAPK
p38,
which normally attenuates MEK1/2 signaling, was inhibited
by SB203580, which enhanced the inhibition of apoB100
secretion by nobiletin, conﬁrming that nobiletin signals
through MAPK
erk (Fig. 1C). In contrast with insulin, in-
cubation of cells with the PI3-kinase inhibitor wortmannin
had no effect on the inhibition of apoB100 secretion by
nobiletin (data not shown).
Nobiletin activates signaling through MAPK
erk to reg-
ulate LDLR, MTP, and DGAT1/2 mRNA expression,
independent of the IR or IRS-1. Activation of ERK,
a protein downstream of MEK1/2, has been implicated in
the regulation of apoB100 secretion (14,20). In HepG2
cells, the time course of nobiletin-induced activation of
ERK1/2 was rapid and concentration dependent, with peak
phosphorylation occurring at 15 min. (Fig. 2A and B). To
determine whether MAPK
erk activation by nobiletin was
mediated through activation of the IR, we examined acute
phosphorylation of both the IR and IRS-1. In contrast with
insulin, nobiletin did not induce tyrosine phosphorylation
of the IR or IRS-1 (Fig. 2C and D), demonstrating that
nobiletin rapidly activates MAPK
erk through a distinct
mechanism. Decreased MTP and increased LDLR expres-
sion have been linked to inhibition of apoB100 secretion
(20,22). Like insulin, MAPK
erk activation by nobiletin de-
creased MTP mRNA (230%) and increased LDLR mRNA
2.5-fold (Fig. 2E). Nobiletin signiﬁcantly decreased DGAT1
and DGAT2 mRNA expression through activation of
MAPK
erk (Fig. 2E).
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ity, but does not increase cellular TG synthesis or
mass accumulation. The increased LDLR expression
resulted in enhanced LDLR activity as diI-LDL uptake in-
creased in HepG2 cells incubated with either nobiletin or
insulin (Fig. 3A). Nobiletin reduced MTP activity (225%)
(Fig. 3B), whereas insulin had no effect, suggesting that
inhibition of MTP by nobiletin was direct and not related to
decreased mRNA expression. Insulin is known to stimulate
FA and TG synthesis (22); however, nobiletin had no effect
on either parameter (Fig. 3C and D). Consistent with de-
creased DGAT1/2 mRNA, TG synthesis and TG mass were
signiﬁcantly lower in nobiletin-treated cells, when com-
pared with insulin-treated cells (Fig. 3D and E). Nobiletin
increased CPT1-a and PGC1-a mRNA, which was associ-
ated with a modest, but not signiﬁcant, increase in cellular
FA oxidation (Fig. 3F and G).
Nobiletin prevents diet-induced weight gain and
reduces dyslipidemia in high-fat fed Ldlr
2/2 mice. In
Ldlr
2/2 mice, a Western diet induces many aspects of the
metabolic syndrome including obesity, hyperinsulinemia,
hyperlipidemia, and glucose intolerance (37). Using this
model, we examined the effect of nobiletin on metabolic
parameters including VLDL-TG production, hepatic stea-
tosis, insulin resistance, and atherosclerosis. Nobiletin-
treated mice resisted the Western diet-induced weight gain
(Fig. 4A) despite no difference in caloric intake or intestinal
TG absorption (Fig. 4B and C). The Western diet increased
fasting plasma TG (threefold) and cholesterol (2.8-fold)
compared with chow-fed animals. Nobiletin signiﬁcantly de-
creased both plasma lipids by 35% (Fig. 4D and E). Metabolic
studies with tyloxapol, which inhibits lipolysis of lipoproteins
derived from both the intestine and the liver, demonstrated
an overproduction of TG-rich lipoproteins induced by the
Western diet (Fig. 4F). When compared with Western-fed
mice, nobiletin supplementation signiﬁcantly reduced the
VLDL-TG secretion rate (Fig. 4G). Elevated plasma non-
esteriﬁed fatty acid (NEFA) and glycerol, characteristic of
insulin resistance, were observed in Western-fed animals,
both of which were normalized by nobiletin (Fig. 4H and I).
Nobiletin reduces TG in both the liver and intestine
in high-fat fed Ldlr
2/2 mice. The Western diet signiﬁ-
cantly increased liver TG 1.5-fold and cholesteryl ester
(CE) mass 4.8-fold compared with chow (Fig. 5A and B).
Addition of 0.1 and 0.3% nobiletin dose-dependently de-
creased hepatic TG by 44 and 87%, and hepatic CE by 61
and 71%, respectively. The intestine contributes to VLDL-
TG secretion under conditions described for tyloxapol
experiments. Signiﬁcant levels of TG remain within in-
testinal tissue in Western-fed mice following a 6-h fast (Fig.
5C). Nobiletin supplementation completely normalized in-
testinal TG (Fig. 5C), suggesting that nobiletin limits lipid
availability in both liver and intestine for VLDL-TG secre-
tion. Intestinal CE concentrations were unchanged (data
not shown). The Western diet signiﬁcantly increased liver
Srebp1c expression (2.3-fold) compared with chow-fed
mice. Srebp1c was dose-dependently reduced by 0.1%
(235%) and 0.3% nobiletin (280%) (Fig. 5D), suggesting
that reduced de novo lipogenesis contributes to the pre-
vention of hepatic TG accumulation. In contrast with HepG2
cells, nobiletin did not affect hepatic expression of Mttp or
Dgat1/2 (Fig. 5E–G). The marked reduction in hepatic
TG concentrations and VLDL-TG secretion suggested that
nobiletin stimulates FA oxidation. Expression of Cpt1a,
Pgc1a, and rates of FA oxidation were depressed in
Western-fed animals compared with chow. All three param-
eters were signiﬁcantly increased in nobiletin-treated mice
(Fig. 5H–J). Furthermore, nobiletin increased plasma
ketones twofold, comparedwith Western-fed mice (Fig. 5K).
Increased FA oxidation suggested that nobiletin functions
as a PPAR activator. However, using a luciferase reporter
assay in HepG2 cells, nobiletin did not signiﬁcantly activate
PPARa,P P A R g,o rP P A R d (Supplementary Fig. 1). Fur-
thermore, nobiletin had no effect on hepatic Ppara mRNA,
Acox mRNA, or liver weight (data not shown).
Nobiletin prevents hyperinsulinemia and improves
glucose tolerance and insulin sensitivity. Western-fed
mice were hyperinsulinemic (1.4 ng/mL) and moderately
FIG. 1. Nobiletin dose-dependently reduces apoB100 secretion through
activation of MAPK
erk signaling. A: HepG2 cells were incubated in 5%
LPDS-minimum essential medium with insulin or increasing concen-
trations of nobiletin for 24 h. B: HepG2 cells were preincubated for
30 min in the absence or presence of DMSO U0126 (10 mM; active MEK1/2
inhibitor) or U0124 (10 mM; null inactive isoform). C: HepG2 cells were
preincubated for 30 min in the absence or presence of DMSO, SB203580
(10 mM; active p38 MAPK inhibitor), or SB248080 (10 mM; null inactive
isoform), followed by an additional 19.5-h incubation in the absence or
presence of DMSO, insulin (100 nM), or nobiletin (10 mM). Media were
collected, and apoB100 was measured by immunoblotting. Results are
reported as a percentage of the DMSO control. Values are means 6
SEM, and different letters are statistically different (P < 0.05).
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and 6.8 mmol/L), whereas fasting plasma insulin and glucose
were signiﬁcantly decreased by 0.3% nobiletin (0.4 ng/mL
and 6.2 mmol/L), respectively (Fig. 6A and B). Glucose
tolerance tests revealed that nobiletin normalized the im-
paired glucose tolerance observed in Western-fed mice
(Fig. 6C). Nobiletin signiﬁcantly improved the impaired
insulin tolerance in Western-fed mice such that the area
under the glucose curve was similar to chow-fed mice (Fig.
6D). The Western diet induced TG accumulation in gas-
trocnemius and quadriceps, whereas muscle lipid deposition
was completely prevented by nobiletin supplementation
(Fig. 6E).
To determine the locus of insulin resistance in Western-
fed mice and its prevention by nobiletin, hyperinsulinemic
euglycemic clamp studies were performed to assess
whole-body insulin sensitivity as well as hepatic versus
peripheral insulin action. As shown in Fig. 6F, the glucose
infusion rate required to maintain euglycemia was signiﬁ-
cantly increased twofold in nobiletin-supplemented mice
compared with Western-fed mice. This improved insulin
sensitivity was explained by both an increase in peripheral
glucose disposal (Fig. 6G) and enhanced suppression of
hepatic glucose production (HGP) (Fig. 6H and I). During
the clamp, HGP was signiﬁcantly lower (270%) in nobiletin-
supplemented mice compared with Western-fed mice be-
cause of an increase in the ability of insulin to blunt HGP.
Hepatic gluconeogenesis was assessed using a pyruvate
tolerance test in which injection of the gluconeogenic
substrate pyruvate increases blood glucose by promot-
ing hepatic gluconeogenesis. In Western-fed mice, pyru-
vate increased blood glucose concentrations to a greater
FIG. 2. Nobiletin, unlike insulin, doesnot activate the IRand IRS-1 to stimulate ERK phosphorylation. A: HepG2 cells were incubated for 16 h in serum-
free minimum essential medium (containing 0.5% insulin-free, FA-free BSA) and treated with DMSO, insulin (100 nM), or nobiletin (10 mM) for up to
30 min. B: HepG2 cells incubated in serum-free minimum essential medium were treated with DMSO (control) and increasing concentrations of
nobiletin for 15 min. Total and phosphorylated ERK1/2 were measured by immunoblot analysis. Values are reported as a fold change compared with
DMSO control and are means 6 SEM. C and D: HepG2 cells were preincubated in serum-free minimum essential medium followed by addition of DMSO,
insulin (100 nM), or nobiletin (10 mM) for up to 60 min, and cell lysates were immunoprecipitated with IR (C)o rI R S - 1( D)a n t i b o d i e s .P r o t e i n sw e r e
s e p a r a t e db y6 %S D S - P A G Ea n dm e m b r a n e sp r o b e dw i t hI R( C) or IRS-1 (D) and phosphotyrosine antibodies. E: HepG2 cells in 5% LPDS-minimum
essential medium were preincubated for 30 min with DMSO, the MEK1/2 inhibitor UO126 (10 mM), or its null inactive isoform UO124 (10 mM) followed
by a 5.5 h incubation with DMSO, insulin (100 nM), or nobiletin (10 mM). mRNA levels were quantitated by qRT-PCR. Results are normalized to
GAPDH and reported relative to the DMSO control. Values are means 6 SEM; n ‡5. Different letters are statistically different (P < 0.05).
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mals (Fig. 6J).
Nobiletin inhibits diet-induced obesity and adipocyte
hypertrophy. Treatment with 0.1% nobiletin had no effect
on diet-induced adiposity, whereas 0.3% nobiletin com-
pletely prevented adipose tissue accumulation (Fig. 7A and
Supplementary Fig. 2A and B). Western-fed mice exhibited
elevated plasma leptin levels (Fig. 7B) and adipocyte hy-
pertrophy in epididymal fat pads and brown adipose tissue
(Fig. 7C and D and Supplementary Fig. 3A and B), which
were completely normalized by 0.3% nobiletin. These
changes were independent of caloric intake (Fig. 4B) and
muscle mass (Supplementary Fig. 2C and D), suggesting
effects on energy metabolism. Total energy expenditure
increased signiﬁcantly in mice fed 0.3% nobiletin, com-
pared with both Western and chow-fed mice. This was
primarily because of enhanced energy expenditure during
the dark cycle (Fig. 7E). Respiratory quotients were not
statistically different among the dietary groups: 0.95 6 0.02,
0.87 6 0.02, and 0.93 6 0.02 for chow, Western, and Western
plus 0.3% nobiletin, respectively.
Nobiletin prevents dyslipidemia, hepatic steatosis, and
atherosclerosis in Ldlr2/2 mice. To evaluate whether cor-
rection of dyslipidemia and insulin resistance by nobiletin
prevents atherosclerosis, mice were fed chow or the Western
diet 60.3% nobiletin (weight/weight) for 8 or 26 weeks. By 26
weeks, Western-fed mice developed extensive dyslipidemia.
Both plasma TG and cholesterol concentrations increased
FIG. 3. Nobiletin modestly decreases FA and TG synthesis and TG mass in HepG2 cells despite inhibition of MTP activity in HepG2 cells. A: HepG2
cells in 5% LPDS-minimum essential medium were preincubated for 19 h with insulin (50 nM, 100 nM) or nobiletin (5 mM, 10 mM) followed by a 5-h
incubation with 10 ng/mL diI-LDL. diI-LDL ﬂuorescence was measured by ﬂow cytometry. B: MTP activity was measured in homogenates from HepG2
cells incubated for 24 h with DMSO, insulin (100 nM), nobiletin (10 mM), or a speciﬁc MTP inhibitor, BMS-197636. Values are reported as percentage
of controls and are means 6 SEM. C: HepG2 cells were incubated in 5% LPDS-minimum essential medium with DMSO, insulin (100 nM), or nobiletin
(10 mM) for 24 h in the presence of [
14C]acetate. Lipids were extracted and saponiﬁed, and rates of FA synthesis are presented as nanomoles FA
formed per milligrams cell protein. TG synthesis (D) and TG mass (E) were determined in HepG2 cells incubated with DMSO, insulin (100 nM), or
nobiletin (10 mM) for 19 h followed by a 5-h incubation with [1-
14C]oleic acid plus 0.1 mM cold oleic acid (D) or 0.1 mM cold oleic acid alone (E).
Lipids were extracted with hexane-isopropanol and quantiﬁed. F: The mRNA abundance of CPT1a, ACOX,a n dPGC1a was quantiﬁed by qRT-PCR in
HepG2 cells treated for 6 h with DMSO or nobiletin (10 mM). G: FA oxidation was determined in HepG2 cells by conversion of [
3H]palmitate to [
3H20]
in cells treated with nobiletin (10 mM) or AICAR (500 mM). All values are means 6 SEM; n ‡5. Different letters are statistically different (P < 0.05).
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mentation signiﬁcantly decreased plasma TG and cholesterol
by 74 and 67%, respectively (Fig. 8A and B). The Western diet
induced marked hepatic steatosis resulting in a 7.3-fold in-
crease in liver TG and a 13-fold increase in liver CE com-
pared with chow-fed mice. Nobiletin almost completely
prevented hepatic lipid accumulation such that lipid levels
were similar to chow-fed mice (Fig. 8C and D). At 26 weeks,
Western-fed mice continued to be hyperglycemic and hyper-
insulinemic. Nobiletin normalized fasting glucose and insulin
concentrations to levels observed in chow-fed mice (Fig. 8E
and F).
After 8 weeks, Western-fed mice demonstrated modest
lesion development as assessed by Oil Red O-staining, within
the aortic sinus, when compared with chow-fed mice or
nobiletin-treated mice (Fig. 8G). After 26 weeks on diet,
lesion area within the aortic sinus of Western-fed animals
was signiﬁcantly increased by 12-fold, compared with chow-
fed animals. Nobiletin supplementation signiﬁcantly reduced
plaque area by 83%, compared with Western-fed mice (Fig.
8H and I).
DISCUSSION
In the current study, we evaluated the role of nobiletin in
the regulation of apoB100 secretion from hepatoma cells
and the ability of nobiletin to prevent dyslipidemia, insulin
resistance, and atherogenesis induced in mice by high-fat
feeding. We show that nobiletin inhibits apoB100 secre-
tion from HepG2 cells through activation of MAPK
erk,i na
manner similar to insulin, although nobiletin does not ac-
tivate the IR and IRS-1. In Ldlr
2/2 mice, nobiletin attenu-
ates diet-induced obesity, hepatic steatosis, VLDL-TG
secretion, and dyslipidemia and increases hepatic FA ox-
idation. Furthermore, nobiletin restores glucose tolerance
and insulin sensitivity in liver and peripheral tissues. Col-
lectively, improvement in these metabolic parameters
leads to the prevention of atherosclerosis.
FIG. 4. Nobiletin dose-dependently inhibits weight gain in Western-fed Ldlr
2/2 mice. Mice were fed diets for 8 weeks and fasted for 6 h (n =
6/group). Body weight was measured biweekly (A), and caloric intake was measured daily over 8 weeks (B). C: TG absorption using a fecal dual
isotope method. Percent TG absorption was calculated from the radiolabel ratio in feces collected over 48 h. D and E: Plasma TG and cholesterol
concentrations. F: Mice were injected with tyloxapol, and TG was measured in the plasma VLDL/IDL fraction (d <1.019 g/mL) at 0 and 120 min
(n =5 –6 mice/group/time point). G: The production rate was determined as micromoles per liter per hour. H and I: Plasma NEFA (H) and glycerol
concentrations (I) are shown. Data represent the mean 6 SEM, and different letters are statistically different (P < 0.05).
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creased concentrations of apoB100-containing lipoproteins.
Previously, it has been shown that the citrus ﬂavonoid
naringenin inhibits apoB100 secretion from HepG2 cells
through a mechanism similar to insulin (20,22). Nobiletin is
a signiﬁcantly more potent inhibitor; its half-maximal in-
hibitory concentration (IC50) for reduction of apoB100
secretion from HepG2 cells is ;10-fold lower, compared
with naringenin (29). Nobiletin, like insulin, decreases
apoB100 secretion through rapid activation of signaling
through MAPK
erk, leading to the enhanced expression and
activity of the LDLR, decreased expression, and activity of
MTP and decreased expression of DGAT1/2, all of which
are known to contribute to the inhibition of apoB100 se-
cretion (14,20–22). Nobiletin activates MAPK
erk through
a mechanism distinct from insulin, since nobiletin did not
induce tyrosine phosphorylation of the IR or IRS-1. This
observation demonstrates that nobiletin has the potential
to regulate hepatic lipid and lipoprotein metabolism, in
vivo, in the context of insulin resistance.
Activation of MAPK
erk signaling by polyphenols in HepG2
cells has been shown to increase LDLR mRNA (38–40).
Naringenin increases LDLR expression in HepG2 cells and
requires enhanced processing of SREBP1 (22). Berberine
increases LDLR mRNA via ERK1/2, through a mechanism
involving message stabilization, resulting in reduced plasma
LDL-C concentrations in vivo (41). Activation of MAPK
erk
by nobiletin also decreased DGAT1/2 mRNA expression.
In HepG2 cells, inhibition of MAPK
erk enhances DGAT1/2
expression and microsomal TG availability for VLDL as-
sembly (14). We demonstrate that nobiletin decreases
expression of DGAT mRNA, which is associated with re-
duced TG synthesis, indicating one mechanism whereby
nobiletin limits TG availability for apoB100 secretion. MTP
mRNA and MTP activity were both decreased by nobiletin
in HepG2 cells, similar to the effect of naringenin (21,32).
FIG. 5. Nobiletin improves hepatic steatosis in Ldlr
2/2 mice fed a Western diet for 8 weeks. Mice were fed diets for 8 weeks and fasted for 6 h (n =
6/group). Liver TG (A) and CE mass determined by lipid extraction (B) are shown. C: Intestinal TG content at sacriﬁce. D–I: Expression of Srebf1c
(Srebp1c), Mttp, Dgat1, Dgat2, Cpt1a, and Pgc1a mRNA relative to Gapdh mRNA, quantitated by qRT-PCR. J: Fatty acid oxidation in liver (n =4 –
6/group) determined by [
3H]palmitate conversion to
3H2O. K: Plasma ketone bodies were quantitated by a kinetic rate method. Data represent the
mean 6 SEM, and different letters are statistically different (P < 0.05).
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contributes to reduced apoB100 secretion in nobiletin-
treated HepG2 cells.
To extend our in vitro ﬁndings, we determined the effect
of nobiletin in high-fat fed Ldlr
2/2 mice, a model of diet-
induced insulin resistance and atherosclerosis (37). Nobi-
letin supplementation resulted in a dramatic reduction in
both hepatic and intestinal TG accumulation, attenuation
of VLDL-TG secretion, and normalization of glucose ho-
meostasis and conferred an almost complete resistance to
obesity, without effect on caloric consumption or fat ab-
sorption. Many variables can contribute to hepatic lipid
accumulation including increased ﬂux of dietary and lib-
erated visceral FA, increased FA synthesis, and reduced
FA oxidation (8). In contrast with the Western diet, nobi-
letin normalizes insulin concentrations, reduces plasma
NEFA, and decreases hepatic Srebp1c mRNA expression
demonstrating that nobiletin reduces both NEFA ﬂux and
endogenous lipogenesis. It has been shown that blocking
the effect of hyperinsulinemia on Srebp1c-stimulated li-
pogenesis dramatically decreases hepatic TG content and
VLDL-TG secretion (12,13). Nobiletin also decreases hepatic
TG availability through enhanced expression of Pgc1a
and Cpt1a, leading to a signiﬁcant increase in hepatic
FIG. 6. Nobiletin improves glucose utilization and insulin sensitivity in Ldlr
2/2 mice fed a Western diet for 8 weeks. Mice were fed diets for 8 weeks
and fasted for 6 h (n = 6/group). A: Plasma insulin was measured by enzyme-linked immunosorbent assay. B: Blood glucose was measured by
glucometer. Glucose tolerance tests (C) or insulin tolerance tests (D) were performed in 6-h fasted mice by intraperitoneal injection of 1 g/kg
glucose (C) or 0.6 IU/kg insulin (D) and blood glucose measured from 0 to 60 or 120 min. Glucose utilization or insulin sensitivity was determined
as the area under the curve (AUC; inset graphs). E: TG content of gastrocnemius and quadriceps muscle. Hyperinsulinemic-euglycemic clamps
were conducted in Ldlr
2/2 mice fed the Western diet or the Western diet supplemented with 0.3% nobiletin for 8 weeks. F: glucose infusion rate
during the last 60 min of the clamp. G: Whole-body glucose uptake (Rd) during the clamp. HGP (H) and percent suppression of HGP (I) during the
clamp are shown. J: Pyruvate tolerance tests were performed in 16-h fasted mice by intraperitoneal injection of pyruvate (2 g/kg). Data represent
the mean 6 SEM, and different letters are statistically different (P < 0.05).
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CoA decarboxylase, an enzyme that stimulates b-oxidation,
decreases hepatic TG content, reduces plasma NEFA, pre-
vents hyperinsulinemia, and improves whole body glucose
tolerance and insulin sensitivity (42). These data indicate
that prevention of the hepatic lipid load by nobiletin limits
lipid availability for hepatic lipid storage, lipoprotein se-
cretion, and lipid deposition in peripheral tissues.
The striking improvement in hepatic steatosis and pre-
vention of adiposity in nobiletin-treated mice was associ-
ated with a signiﬁcant reduction of TG in muscle. Reduced
muscle TG is known to restore muscle function and in-
sulin sensitivity (43–45). Studies in ob/ob mice treated
with a PPARa agonist demonstrated improved insulin
sensitivity in both liver and muscle, which was accom-
panied by a signiﬁcant reduction of lipid accumulation in
both tissues (46). This concept is supported in the cur-
rent study by nobiletin-induced normalization of peripheral
glucose disposal, which is primarily a reﬂection of in-
creased skeletal muscle insulin sensitivity. Furthermore,
nobiletin improved hepatic insulin sensitivity as evidenced
by enhanced insulin-mediated suppression of HGP and
gluconeogenesis; assessed in hyperinsulinemic-euglycemic
clamps and pyruvate tolerance tests, respectively. Nobiletin-
induced increases in hepatic FA oxidation and reduced
lipogenic gene expression would be expected to improve
hepatic insulin sensitivity and enhance insulin-mediated
suppression of HGP. The restored insulin sensitivity and
glucose disposal in peripheral tissues of nobiletin-treated
mice could be a secondary consequence of reduced ex-
posure of muscle to both VLDL-derived and plasma NEFA.
The prevention of ectopic lipid accumulation by nobi-
letin may be partially mediated through increased energy
metabolism. Addition of nobiletin to the high-fat diet mod-
erately stimulates whole-body energy expenditure, particu-
larly during the dark period, and thus makes a contribution
FIG. 7. Nobiletin prevents adipose tissue accumulation and adipocyte hypertrophy in Ldlr
2/2 mice fed a Western diet for 8 weeks. Mice were fed
diets for 8 weeks and fasted for 6 h (n = 6/group). A: Adiposity index was determined as the weight of epididymal adipose stores per gram of body
weight. B: Plasma leptin concentrations. C and D: Adipocyte size was determined by measuring the diameter (in mm) of adipocytes from hema-
toxylin and eosin-stained sections of epididymal adipose tissue (n = 200 adipocytes/group). E: Energy expenditure was determined via indirect
calorimetry during both the light and dark cycle (6:00 A.M.–6:00 P.M.). Measurements were collected every 15 min, and each data point, expressed as
kilocalories per hour per mouse, represents a rolling average of four time points. Values are the mean 6 SEM, and different letters are statistically
different (P < 0.05).
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fat content. However, nobiletin does not appear to affect
metabolic fuel preference since the respiratory quotient
did not differ among dietary groups. Although cold toler-
ance was not measured, mean body temperatures were
similar among the dietary groups (data not shown) sug-
gesting that brown adipose tissue adaptive thermogenesis
did not contribute to enhanced energy expenditure. In-
terestingly, attenuation of diet-induced adiposity by nobi-
letin does not account entirely for the prevention of
dyslipidemia and hepatic lipid accumulation. Nobiletin at
0.1% had no effect on adiposity but reduced plasma con-
centrations of cholesterol, TG, glycerol, and NEFA to the
same extent as 0.3% nobiletin. Furthermore, 0.1% nobiletin
reduced hepatic TG and CE and reduced muscle lipid ac-
cumulation. However, plasma concentrations of insulin,
glucose, and leptin in 0.1% nobiletin-treated mice were not
different from Western-fed animals. This suggests that
prevention of dyslipidemia and hepatic lipid accumulation
is more sensitive to nobiletin and is independent of de-
creased diet-induced adiposity. The prevention of insulin
resistance, glucose intolerance, and adiposity requires 0.3%
nobiletin, suggesting that over 8 weeks normalization of
these metabolic parameters by nobiletin is mechanistically
linked.
Nobiletin increased hepatic Pgc1a and Cpt1a mRNA,
leading to increased FA oxidation. However, in a luciferase
reporter assay, nobiletin did not activate any PPAR, including
FIG. 8. Nobiletin improves dyslipidemia, hepatic steatosis, and hyperinsulinemia and reduces atherosclerosis in Ldlr
2/2 mice fed a Western diet for
26 weeks. A–F: Mice were fed diets for 26 weeks and fasted for 6 h (n = 12/group). Plasma TG (A) and cholesterol concentrations (B) are shown.
TG (C) and cholesteryl ester concentrations (D) in liver are shown. E: Blood glucose concentrations. F: Plasma insulin concentrations. G and H:
Mice were fed diets for 8 weeks (n = 3/group) or 26 weeks (n = 12/group) and fasted for 6 h before being killed. Representative frozen serial
sections (10 mm) of the aortic sinus, prepared using a cryostat, stained with Oil Red O and counterstained with hematoxylin. I: Lesion area for all
mice at 26 weeks was quantitated and expressed as total plaque area. Values are the mean 6 SEM, and different letters are statistically different
(P < 0.05). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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or liver weight, suggesting activation of FA oxidation was
not mediated through classic PPARa activation. In con-
t r a s tw i t ho u ri nv i t r os t u d i e s ,Dgat1/2 or Mttp mRNA
abundance was unaffected by any dietary treatment. This
is consistent with previous studies in which Mttp expres-
sion is unchanged in hepatic IR–deﬁcient (L1B6Ldlr
2/2),
Lxr
2/2,a n dLdlr
2/2 mice fed a high-fat diet (13,24,47),
suggesting that neither the high-fat diet nor ﬂavonoid
supplementation affect Mttp or Dgat1/2 expression in
this model.
Hyperlipoproteinemia and type 2 diabetes are thought
to contribute synergistically to inﬂammation and athero-
sclerosis (48). Nobiletin-treated mice had substantially
reduced lesion area within the aortic sinus, compared with
Western-fed mice, which was evident as early as 8 weeks
of treatment. These data suggest that nobiletin supplemen-
tation reduces the atherosclerotic disease process, primar-
ily through prevention of dyslipidemia, hepatic steatosis,
and improved insulin sensitivity. In macrophages, nobiletin
has been shown to suppress proinﬂammatory cytokine ex-
pression (49) and reduce the uptake of acetylated LDL (50).
Although not evaluated in this study, a direct effect on in-
ﬂammation and foam cell formation may also contribute to
the attenuation of atherosclerosis.
In conclusion, our studies provide physiological and
molecular evidence that nobiletin regulates hepatic lipid
metabolism to prevent many of the abnormalities asso-
ciated with insulin resistance. The correction of he-
patic steatosis, dyslipidemia, and glucose homeostasis
by nobiletin protects against the development of athero-
sclerosis through a range of mechanisms. The use of
nobiletin provides insight into potential targets for the
treatment of abnormal lipoprotein and glucose metabo-
lism, characteristic of insulin-resistant states, and pre-
mature atherosclerosis.
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